Abstract
Because the brainstem has little functional redundancy, diffuse lesions have been regarded as inoperable. To determine whether local drug therapy can prolong survival in a rodent model of a tumor in such eloquent tissue, lethal doses of F98 and 9L tumor cells were injected into the brainstems of Fischer 344 rats. Five days after inoculations, 0.5 mg/ml solutions of carboplatin were infused at 1 μl/h for 7 days. Compared to control groups that survived 13–17 days with F98 tumors and 22–23 days with 9L tumors, animals locally infused with 0.1 mg of carboplatin survived 27–30 days (Prob > Chi Sq = 0.0003), and 32 days (Prob > Chi Sq = 0.01), respectively. Measurements of tissue platinum levels at autopsy suggested that infusions distributed pharmacologically relevant levels of carbo-platin through a volume of tissue at least 0.5 cm in diameter. The results suggest that chronic low-flow infusions provide a promising approach to therapy for CNS lesions in tissues considered to be inoperable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burke M, Langer R, Brem H: Central nervous system, drug delivery to treat. In: Mathiowitz E (ed) The Encyclopedia of Controlled Drug Delivery. John Wiley & Sons, New York, 1999, pp 184–212
Haroun RI, Brem H: Local drug delivery. Curr Opin Oncol 12: 1887–1893, 2000
Chen W, Lu DR: Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J Microencapsul 16: 551–563, 1999
Chen W, He J, Olson JJ, Lu DR: Direct intracerebral delivery of carboplatin from PLGA microspheres against experimental malignant glioma in rats. Drug Deliv 5: 101–110, 1998
Emerich DF, Winn SR, Hu Y, Marsh J, Snodgrass P, LaFreniere D, Wiens T, Hasler BP, Bartus RT: Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavitywall of debulked tumors. Pharm Res 17: 767–775, 2000
Emerich DF, Winn SR, Snodgrass P, LaFreniere D, Agostino M, Wiens T, Xiong H, Bartus RT: Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. Pharm Res 17: 776–781, 2000
Ram Z, Samid D, Walbridge S, Oshiro E, Viola J, Tao-Cheng J-H, Shack S, Thibault A, Meyers C, Oldfield E: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenyl acetate. Cancer Res 54: 2923–2927, 1994
Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362–1368, 1997
Ikeda Y, Carson BS, Lauer JA, Long DM: Therapeutic effects of local delivery of dexamethasone on experimental brain tumors and peritumoral brain edema. J Neurosurg 79: 716–721, 1993
Hagihara N, Walbridge S, Olson AW, Oldfield EH, Youle RJ: Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 60: 230–234, 2000
Wu Q, Tyler B, Sukay L, Rhines L, DiMeco F, Clatterbuck RE, Guarnieri M, Carson BS, Sr.: Experimental rodent models of brainstem tumors. Vet Pathol 39: 293–299, 2002
Kroin JS, Penn RD: Intracerebral chemotherapy: Chronic microinfusion of cisplatin. Neurosurgery 10: 349–354, 1982
Cartmill M, Punt J: Diffuse brain stem glioma. A review of stereotactic biopsies. Child's Nerv Syst 15: 235–238, 1999
Jackowski A: Brain stem surgery. Brit J Neurosurg 9: 581–584, 1995
Levesque MF, Parker F: MKM-guided resection of diffuse brainstem neoplasms. Oncology 73: 15–18, 1999
Steck J, Friedman WA: Stereotactic biopsy of brainstem mass lesions. Surg Neurol 43: 563–568, 1995
Xu QW, Bao WM, Mao RL, Jiang DJ, Yang GY: Surgical treatment of solid brain stem tumors in adults: a report of 22 cases. Surg Neurol 48: 30–36, 1997
Tamargo RJ, Myseros JS, Epstein JL, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 53: 329–333, 1993
Peterson K, Harsh G, Fisher PG, Adler J, Le Q: Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neuro-Oncol 53: 27–32, 2001
Olivi A, Ewend MG, Utsuki T, Tyler B, Domb AJ, Brat DJ, Brem H: Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 39: 90–96, 1996
Friedman HS, Lovell S, Rasheed K, Friedman AH: Treatment of adults with progressive oligodendroglioma with carboplatin. Med Pediatr Oncology 31: 16–18, 1998
Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH, Bostrom BC, Goldman S, Sender LS, Gardner SL, Li H, Allen JC, Findlay JL, Children's Cancer Group: High-dose carboplatin, thiotepa, and etoposide with autologus stemcell rescue for patients with recurrent medulloblastoma. J Clin Oncol 16: 222–228, 1998
Gruber ML, Glass J, Choudhri H, Nirenberg A: Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am J Clin Oncol 21: 338–340, 1998
Bouffet E, Raquin M, Doz F, Gentet JC, Rodary C, Demeocq F, Chastagner P, Lutz P, Hartmann O, Kalifa C: Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88: 685–692, 2000
Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL: High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292-R305, 1994
Groothuis DR, Ward S, Itskovich AC, Dobrescu C, Allen CV, Dills C, Levy RM: Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 90: 321–331, 1999
Bobo RH, LaskeDW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91: 2076–2080, 1994
Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH: Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissuecannula sealing time. J Neurosurgery 90: 315–320, 1999
Doz F, Berens ME, Dougherty DV, Rosenblum ML: Comparison of the cytotoxic activities of cisplatin and carboplatin 158 against glioma cell lines at pharmacologically relevant drug exposures. J Neuro-Oncol 11: 27–35, 1991
Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DRA, Sleifer DTh: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355: 1075–1076, 2000
Whittle IR, Malcolm G, Jodrell DI, Reid M: Plasma distribution in malignant glioma following intraoperative intravenous infusions of carboplatin. Brit J Neurosurg 13: 132–137, 2000
Shinohara C, Matsumoto K, Kuriyama M, Adachi H, OnoY, Higashi H, Furuta T, Ohmoto T: Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues [Japanese]. Jpn J Cancer Chemother 21: 1163–1168, 1994
Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RJ: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157–2165, 2000
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Academic Press, Orlando, FL, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carson, B.S., Wu, Q., Tyler, B. et al. New Approach to Tumor Therapy for Inoperable Areas of the Brain: Chronic Intraparenchymal Drug Delivery. J Neurooncol 60, 151–158 (2002). https://doi.org/10.1023/A:1020626419269
Issue Date:
DOI: https://doi.org/10.1023/A:1020626419269